Effects of early initiated oestrogen replacement therapy on plasma homocysteine levels in women in surgically induced menopause

References

• Collins P, Rosano G, Casey C, Daly C, Gambacciani M, Hadji P, Kaaja R, Mikkola T, Palacios S, Preston R, et al Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur Heart J 2007;28:2028–2040.
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933–941.
   PubMed Web of Science ®Google Scholar
• Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, et al Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523–534.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–333.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, et al Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701–1712.
   PubMed Web of Science ®Google Scholar
• Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006;13:265–729.
   PubMed Web of Science ®Google Scholar
• Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Weiss NS, Larson EB, Rosendaal FR, Psaty BM. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 2004;292:1581–1587.
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605–613.
   PubMed Web of Science ®Google Scholar
• Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75:898–915.
   PubMed Web of Science ®Google Scholar
• Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995 Oct 4;274:1049–1057.
   PubMed Web of Science ®Google Scholar
• van Baal WM, Smolders RG, van der Mooren MJ, Teerlink T, Kenemans P. Hormone replacement therapy and plasma homocysteine levels. Obstet Gynecol 1999;94:485–491.
   PubMed Web of Science ®Google Scholar
• Berger PB, Herrmann RR, Dumesic DA. The effect of estrogen replacement therapy on total plasma homocysteine in healthy postmenopausal women. Mayo Clin Proc 2000;75:18–23.
   PubMed Web of Science ®Google Scholar
• Andersson A, Brattström L, Israelsson B, Isaksson A, Hamfelt A, Hultberg B. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest 1992;22:79–87.
   PubMed Web of Science ®Google Scholar
• Wouters MG, Moorrees MT, van der Mooren MJ, Blom HJ, Boers GH, Schellekens LA, Thomas CM, Eskes TK. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995;25:801–805.
   PubMed Web of Science ®Google Scholar
• Tallova J, Tomandl J, Bicikova M, Hill M. Changes of plasma total homocysteine levels during the menstrual cycle. Eur J Clin Invest 1999;29:1041–1044.
   PubMed Web of Science ®Google Scholar
• Ungvari Z, Pacher P, Rischak K, Szollar L, Koller A. Dysfunction of nitric oxide mediation in isolated rat arterioles with methionine diet-induced hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 1999;19:1899–1904.
   PubMed Web of Science ®Google Scholar
• Barnabei VM, Phillips TM, Hsia J. Plasma homocysteine in women taking hormone replacement therapy: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Womens Health Gend Based Med 1999;8:1167–1172.
   PubMedGoogle Scholar
• Scarabin PY, Oger E, Plu-Bureau G; EStrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428–432.
   PubMed Web of Science ®Google Scholar
• Kopper NW, Gudeman J, Thompson DJ. Transdermal hormone therapy in postmenopausal women: A review of metabolic effects and drug delivery technologies. Drug Des Devel Ther 2009;2:193–202.
   PubMedGoogle Scholar
• Jacobsen DW. Homocysteine and vitamins in cardiovascular disease. Clin Chem 1998;44:1833–1843.
   PubMed Web of Science ®Google Scholar
• Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042–1050.
   PubMed Web of Science ®Google Scholar
• Mijatovic V, Kenemans P, Netelenbos C, Jakobs C, Popp-Snijders C, Peters-Muller ER, van der Mooren MJ. Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. Fertil Steril 1998;69:876–882.
   PubMed Web of Science ®Google Scholar
• van der Mooren MJ, Wouters MG, Blom HJ, Schellekens LA, Eskes TK, Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994;24:733–736.
   PubMed Web of Science ®Google Scholar
• Kaleli B, Yildirim B, Demir S, Alatas E. Effects of low-dose 17-beta-estradiol plus norethisterone acetate and tibolone on fasting plasma homocysteine levels in postmenopausal women. Acta Obstet Gynecol Scand 2003;82:1107–1111.
   PubMed Web of Science ®Google Scholar
• Lacut K, Oger E, Abalain JH, Moineau MP, Mottier D; SARAH Investigators. Effects of oral and transdermal 17 beta-estradiol combined with progesterone on homocysteine metabolism in postmenopausal women: a randomised placebo-controlled trial. Atherosclerosis. 2004;174:173–180.
   PubMed Web of Science ®Google Scholar
• Bruschi F, Dal Pino D, Fiore V, Parazzini F, Di Pace R, Cesana BM, Melotti D, Crosignani PG. Effect of oral or transdermal hormone replacement therapy on homocysteine levels: a randomized clinical trial. Maturitas 2004;48:33–38.
   PubMed Web of Science ®Google Scholar
• Evio S, Tiitinen A, Turpeinen U, Ylikorkala O. Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels. Fertil Steril 2000;74:1080–1083.
   PubMed Web of Science ®Google Scholar
• Os I, Os A, Sandset PM, Bølling S, Seljeflot I, Djurovic S, Westheim A. Hormone replacement therapy does not affect plasma homocysteine in postmenopausal women with coronary artery disease. Free tissue factor pathway inhibitor antigen, a circulating anticoagulant, is related to plasma homocysteine. Cardiology 2002;98:6–12.
   PubMed Web of Science ®Google Scholar
• Kurtay G, Ozmen B. A comparison of the effects of sequential transdermal versus continuous orally administered hormone replacement therapies on plasma total homocysteine levels in postmenopausal women: a randomized, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 2007;130:206–211.
   PubMed Web of Science ®Google Scholar
• Lobo RA. Postmenopausal hormones and coronary artery disease: potential benefits and risks. Climacteric 2007;10 (Suppl 2):21–26.
   PubMed Web of Science ®Google Scholar
• Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989;114:473–501.
   PubMed Web of Science ®Google Scholar